title: Quantitative FDG-PET: a new biomarker in PMBCL.
abstract: In this issue of Blood, Ceriani et al introduce, in primary mediastinal B-cell lymphoma (PMBCL), a new prognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomography (PET)/computed tomography (CT): the total lesion glycolysis (TLG), which is an index of the glucose uptake by the total tumor burden. This paper is part of the International Extranodal Lymphoma Study Group (IELSG) 26 prospective study designed to evaluate the role of PET in the treatment of PMBCL.
authors: GROUPE HOSPITALIER MONDOR.
authors: Michel
authors: http://orcid.org/0000-0001-5071-3330
authors: M
authors: Meignan
mesh_terms: D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging*; D008297:Male; D008479:Mediastinal Neoplasms / Q000000981:diagnostic imaging*; D009367:Neoplasm Staging / Q000379:methods*; D011877:Radionuclide Imaging